IN BRIEF: BIOG's investee Esperion bought by ArchiMed for USD1 billion

The Biotech Growth Trust PLC - London-based investment trust - Says on Friday, May 1 that its ...

Alliance News 5 May, 2026 | 11:40PM
Email Form Facebook Twitter LinkedIn RSS

The Biotech Growth Trust PLC - London-based investment trust - Says on Friday, May 1 that its investee, Esperion Therapeutics, will be acquired by ArchiMed SAS, a Lyon, France-based private equity firm. BIOG calls Esperion "a US-based commercial biopharmaceutical company focused on drugs targeting cardiovascular diseases." BIOG notes that its pre-announcement stake in Esperion represents 2.5% of BIOG's net asset value. The transaction was priced at USD3.16 per share, or approximately USD1.00 billion, with an additional USD100 million contingent on Esperion's upcoming sales performance.

Current stock price: 1,336.00 pence, closing up 2.5% in London on Tuesday.

12-month change: up 80%

By John Robaina, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Biotech Growth Ord 1,336.00 GBX 2.45

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures